Selank Protocol: Experimental Design, Not Clinical

A Selank protocol that cites registered trials is citing artefacts. A keyword search of a trial registry returns nine interventional studies for this compound, and reading their titles shows that not one of them is a study of it.

That is not a criticism of the registry. It is how text search works: a query matches a string anywhere in a record, including in a sponsor's name, a background paragraph, a list of concomitant medications or a similarly spelled term. The count is a property of the index, not of the literature, and it is the single most reliable way to catch a page that did not open the records.

What those nine records actually are

Six rows, no trial of this peptide. Anyone who writes that nine trials exist has read the counter above the results list. Anyone who writes that a specific registry identifier belongs to this compound has gone further and attached a number to a record that studies something else. No trial registry identifier should be cited for this compound at all.

Why the mistake is so easy to make

The failure is structural rather than careless. A registry search box returns a count instantly, and the count carries the visual authority of a database result. Opening nine records and reading their titles takes several minutes and produces a worse looking answer, which is that the number is zero.

The same asymmetry runs through most secondary writing about research peptides. Checking is slower than citing, and a citation that turns out to be a false match is indistinguishable, in a finished article, from one that was verified. This is why the identifier itself is worth treating as a claim to be checked rather than as evidence, particularly when it appears in a list rather than in a sentence that describes what the study found.

What a protocol is, in the sense that matters

In research use, a protocol is the controlled document written before the first participant is enrolled. It specifies who may enrol and who may not, how participants are allocated between arms and how that allocation is concealed, who is blinded, exactly what is administered in what formulation by what route, what is measured and when, how the data will be analysed, what counts as an adverse event and where it goes, and who is responsible if someone is harmed.

Each of those sections exists because something went wrong without it. Eligibility criteria define the population a result applies to. Concealed allocation stops the person enrolling participants from steering healthier ones into the treatment arm. Blinding prevents expectation from becoming the effect, which matters more here than almost anywhere, because anxiety outcomes are rating scales completed by people and placebo response in anxiolytic research is large. A pre specified primary outcome stops a study from being rescued afterwards by whichever measurement happened to move.

Selank protocol documents: what the circulating version omits

The version that circulates online is an administration schedule: substance, route, quantity, frequency, duration. It is one line of the intervention section with everything else removed.

What a circulating Selank protocol omits is not paperwork. It is every element that makes an observation interpretable. Without a control arm, a change cannot be separated from the natural course of anxiety, which fluctuates on its own and is usually worst at the moment someone decides to try something. Without blinding, the outcome measure responds to the expectation of the person reporting it. Without a pre specified endpoint, the favourable observation is selected after the fact. Without adverse event definitions, harms are unrecorded rather than absent.

There is a further omission specific to material bought as a research chemical. A trial administers a characterised batch with release testing behind it, covering identity, content, purity and, for an injectable presentation, sterility and endotoxin. Research chemical supply requires none of that, so the intervention line does not even specify what was administered, only what it was called.

Checking a claimed registry citation takes about a minute, and it is worth describing because it is the concrete skill this whole topic turns on. Open the record rather than the search results page. Read the official title, which usually names the intervention outright. Then read the interventions field itself, which lists what is administered in each arm, and the sponsor, which is often a hospital or university with an obvious research programme in something else. If the compound in question appears nowhere in either field, the record matched on background text and the citation is empty. Finally, look at whether results have been posted, because a record with no results section is a plan and not a finding, whatever it studies.

Run that on the records returned for this compound and every one fails at the second step. The intervention is an antiseizure medicine, or a stimulation device, or a course of psychotherapy. Nothing in the set administers the peptide to anyone.

The Russian clinical protocols, and why you cannot read them

This compound is a synthetic heptapeptide derived from tuftsin, developed in Russia, where it is a registered medicine studied principally as an anxiolytic. Clinical work stands behind that registration, and that literature is real.

It is also, from outside, largely unretrievable. Much of it is published in Russian in journals not comprehensively indexed in the databases most readers search, prospective registration was not the norm in the same way, and the regulatory dossier is not public in the form a reader could examine. So the protocols exist, and a reader outside that system generally cannot inspect their eligibility criteria, blinding arrangements, pre specified outcomes or analysis plans.

That produces a position with two halves, and dropping either one distorts it. Real clinical use and regulatory approval in one jurisdiction, and an absence from the Western evidence system that is a fact about access and convention rather than a verdict on the molecule. A page that reports only the first is selling. A page that reports only the second, usually on the strength of a failed English search, is mistaking its own search results for the state of the world.

What an individual record could honestly be

Someone determined to generate information rather than an anecdote can borrow the elements even without the study.

Write down the outcome and the instrument before starting, and use the same instrument on a fixed schedule rather than recalling how the month felt. Decide in advance how long the observation runs and what result would count as nothing happening. Hold the obvious confounders constant, particularly sleep, alcohol, caffeine and workload, and record deviations rather than smoothing them. Publish the record whichever way it comes out.

That still produces one unblinded person with no control group, which cannot establish that a compound did anything. It removes the three failure modes that make most circulating accounts unreadable: outcome selection after the fact, recall reconstructed to fit a conclusion, and quiet abandonment when nothing happens. Honest weakness is more useful than misleading strength, and it is the most a single person can produce without the apparatus a protocol describes.